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Lkb1 inactivation drives lung cancer lineage
switching governed by Polycomb Repressive
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Adenosquamous lung tumours, which are extremely poor prognosis, may result from cellular
plasticity. Here, we demonstrate lineage switching of KRASþ lung adenocarcinomas (ADC) to
squamous cell carcinoma (SCC) through deletion of Lkb1 (Stk11) in autochthonous and transplant
models. Chromatin analysis reveals loss of H3K27me3 and gain of H3K27ac and H3K4me3 at
squamous lineage genes, including Sox2, DNp63 and Ngfr. SCC lesions have higher levels of the
H3K27 methyltransferase EZH2 than the ADC lesions, but there is a clear lack of the essential
Polycomb Repressive Complex 2 (PRC2) subunit EED in the SCC lesions. The pattern of high
EZH2, but low H3K27me3 mark, is also prevalent in human lung SCC and SCC regions within
ADSCC tumours. Using FACS-isolated populations, we demonstrate that bronchioalveolar stem
cells and club cells are the likely cells-of-origin for SCC transitioned tumours. These findings shed
light on the epigenetics and cellular origins of lineage-specific lung tumours.
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L
ung adenocarcinoma (ADC) and squamous cell carcinoma
(SCC) are regarded as segregated entities of non-small-cell
lung cancer. These two tumour types largely have unique
genetic profiles, with KRAS and EGFR activation common
in ADC, while PTEN inactivation, PI3KCA activation and
NOTCH2 activation are common in SCC tumours1,2. However,
there are cases of mixed histology tumours, where at least
10% of the biopsied tumour cells have one histology (either ADC
or SCC) and the remainder are the other histology3.
Adenosquamous (ADSCC) disease accounts for 2–3% of all
diagnoses, though this diagnosis can only be made with wedge
biopsy or tumour resection, which could lead to underestimation
of its prevalence in patient populations3,4. ADSCC is a
particularly poor prognosis tumour type5,6, and genetic studies
have demonstrated that both histological components share
mutations, suggesting a monoclonal tumour origin7. Notably, in
many cases of disease progression after targeted therapy for EGFR
mutation, when it is clinically justifiable to take a second biopsy,
conversion of ADC to SCC has been observed8. Given these data,
a better understanding of lung cancer lineage relationships could
shed light on both the origins of lung cancer and how to
overcome therapeutic resistance.
SCCs have long been proposed to arise from tracheal basal
cells and ADCs have been proposed to arise from alveolar
type II (AT2) cells or club (Clara) cells, due to markers of these
cell types being present in the malignant lesions4,9. However,
given the shared genetics of ADC and SCC lesions in ADSCC
tumours, it must be possible for certain lung cells to drive
both histologies. Basal cells, which express nerve growth
factor receptor (NGFR), p63 and cytokeratin 5 (KRT5), serve as
stem cells for the trachea, main bronchi and upper airways. Basal
cells can replace the pseudostratified epithelium including
secretory club cells, mucus-producing goblet cells and ciliated
cells10–12. In more distal airways, club cells are a self-renewing
population that maintain the ciliated cells13; subsets of club cells
can give rise to ciliated and club cell lineages after injury14,15.
In the alveolar space where gas exchange is carried out by alveolar
type I cells, the surfactant-expressing AT2 cells act as stem
cells16,17. Cells expressing club cell secretory protein (CCSP),
including bronchioalveolar stem cells (BASCs), can give rise to
AT2 cells18–22. There is also extensive plasticity in the lung
and tracheal epithelium, as club cells can give rise to basal
cells23, and may give rise to KRT5þ /p63þ cells or alveolar cells
under certain injury conditions24,25. Cellular lineage switching,
either in the normal situation or in cancer, could be modulated
by epigenetic mechanisms, including histone modification
governed in part by the Polycomb Repressive Complex 2 (PRC2).
Genetically engineered mouse models are unparalleled in their
capacity to allow the study lung tumour origins and evolution.
Using a LSL:KrasG12D/þ ; Lkb1flox/flox (LSL¼ Lox-stop-Lox)
mouse model of lung cancer, we demonstrated previously that
Lkb1 inactivation dramatically accelerated KRAS-driven lung
cancer progression and changed the tumour spectrum from
purely ADC to ADC and SCC26. While KRAS is a common
oncogene in lung ADC, LKB1/STK11, encoding a serine-
threonine kinase implicated in energy sensing and cell polarity,
is notable as being among the most commonly mutated
tumour suppressors in ADC2. Additionally, mutations in LKB1
predominantly co-occur with KRAS activating mutations27,28.
Subsequent studies with the LSL:KrasG12D/þ ; Lkb1flox/flox mouse
model demonstrated that the SCC tumours arise later during
tumour progression than ADC and that SCCs are characterized
by decreased lysyl oxidases and increased reactive oxygen
species29–31. However, because of the simultaneous activation
of KRAS and inactivation of Lkb1, it remained unclear if
a unique pool of SCC competent cells were transformed only
when Lkb1 was deleted, or if existing KRAS-induced ADC could
convert to a squamous fate in response to Lkb1 deletion.
Furthermore, due to the intranasal inhalation method
to introduce Cre to drive the genetics, the cell-of-origin of
this tumour type was unknown.
Here, we describe a stepwise mouse model of lung tumorigen-
esis that strongly supports the theory that established ADC cells
can transition to SCC fate upon additional genetic perturbations,
such as Lkb1 deletion. Using this model, we found that
de-repression of squamous genes through loss of Polycomb-
mediated gene repression accompanies the squamous transition.
We also show that club cells and BASCs are the most
fit populations to give rise to adenosquamous tumours. Together
these data add to our understanding of the underlying epigenetic
programmes and cellular origins of lineage-specific lung tumours.
Results
Lkb1 deletion drives SCC transition of established KRAS ADCs.
Previously, we showed that Stk11 (Lkb1) deletion concomitant
with induction of oncogenic KRAS drove acquisition of aggressive
tumour characteristics, including SCC transition, not observed
in KRAS tumours when Lkb1 is intact26. These data were
confounded by the fact that Lkb1 mutations are relatively
infrequent in pure SCC tumours (2%, see ref. 1). However, the
model of KRAS and Lkb1 is actually a mixed histology model,
containing ADC, SCC and mixed ADSCC tumours. Thus, we
hypothesized that LKB1 mutations may be more frequent in
patient lung ADSCC samples. Data from a published study32 and
from a cohort of ADSCC tumours at DFCI showed that of
23 ADSCC tumour cases, 6 harboured LKB1 inactivation. These
data suggest that LKB1 mutations may be more frequent (26.1%),
or at least as frequent, in ADSCC tumours as in ADC tumours
(15.6%, 111 of 602 ADC tumours, P¼ 0.24). Together with
data demonstrating KRAS is often activated in ADSCC
tumours33, we propose that ADSCC in KRAS/Lkb1 mice is
a clinically relevant recapitulation of the genetics found in
human lung adenosquamous patients.
To dissect the contributions of KRAS and Lkb1 mutations
during lung tumorigenesis, we used the dual recombinase model
to activate oncogenic KRAS and vary the time-point of Lkb1
deletion. Our model includes that alleles FSF:KrasG12D/þ ;
FSF:R26:CreERT2; Lkb1flox/flox (FSF¼ Fret-Stop-Fret) and
combines flippase-FlpO-Fret and tamoxifen (Tam) inducible
Cre-loxP recombination to make KRASG12D activation and
Lkb1 inactivation separable (Fig. 1a). Mice were randomized
into four arms: (1) KRAS activation with Lkb1 deletion at
the same time (concomitant), (2) KRAS activation followed
by Lkb1 deletion after 2 weeks, (3) KRAS activation followed by
Lkb1 deletion after 10 weeks and (4) KRAS activation alone
(Fig. 1a). Compared to mice with KRAS activation alone, overall
survival of the cohorts was shortest when Lkb1 was deleted
concomitant with KRAS activation, and was significantly
shortened when Lkb1 was deleted either 2 weeks or 10 weeks
after KRAS activation (P¼ 0.0081 KRAS alone versus 10 weeks,
Fig. 1b). We confirmed that tamoxifen administration was
causing bi-allelic deletion of Lkb1 by performing western blot
on whole tumour extracts (Supplementary Fig. 1a). In addition to
accelerated tumour growth and reduced survival, lymph node and
distant tumour metastases were present in all three cohorts in
which Lkb1 was deleted (Supplementary Fig. 1b). We next sought
to determine if deletion of Lkb1 long after KRAS activation could
drive the increased histology spectrum observed previously26.
In the two cohorts where Lkb1 was deleted after induction of
KRAS, we observed acquisition of squamous characteristics to
the same degree as observed with the concomitant model, with
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approximately 40% of mice harbouring at least one tumour
with purely squamous characteristics at the end of the study
(P¼ 0.96 concomitant versus 10 week; Fig. 1c). Consistent with
previous observations34, tumours that develop when KRAS is
activated by FlpO were uniformly low-grade lung tumours
that always present as glandular adenomas and ADCs (Fig. 1d).
In Lkb1-deleted tumours, purely squamous and transitioning
tumours with areas of both ADC and SCC histology, as
determined by immunohistochemistry (IHC) for the squamous
markers KRT5, p63 and SOX2, were present (Fig. 1e,f).
By contrast, the distal lung marker TTF1 (NKX2.1) was highest
in the ADC lesions, and decreased during squamous transition.
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Figure 1 | Lkb1 deletion drives SCC transition and tumour progression in established KRAS tumours. (a) Schematic of the four cohorts of mice used in
this study: (1) KRAS activation with Lkb1 deletion at the same time (FlpOþTam), (2) KRAS activation followed by Lkb1 deletion after 2 weeks
(FlpO-2weeks-Tam), (3) KRAS activation followed by Lkb1 deletion after 10 weeks (FlpO-10 weeks-Tam) and (4) KRAS activation alone (FlpO).
(b) Kaplan–Meier survival of the four cohorts, n indicated in the figure, Po0.0001 between FlpOþTam and 2-week Tam, P¼0.0081 between 10-week Tam
and FlpO. P values in b represent log-rank test. (c) Percentage of mice with at least one purely squamous lesion as determined by histology at end point in
the four cohorts, n and P-values indicated in the figure, P-values represent w2-test. (d) Haematoxylin and eosin staining of tumours at 10 weeks post FlpO
show only adenocarcinoma histology. Scale bar, 50mm. (e) Haematoxylin and eosin staining of tumours at 20 weeks post tamoxifen shows tumours that
are undergoing transition from adenocarcinoma to squamous cell carcinoma histology, scale bar, 50mm. (f) Validation of tumour subtyping by
immunohistochemistry for TTF1 (NKX2.1), KRT5, p63, and SOX2. Scale bar, 50mm. See also Supplementary Fig. 1a–c.
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Consistent with the microenvironment also being affected35,36,
we observed that the tumour-associated myeloid cells changed
during transition from ADC to SCC. As previously observed37,
ADC lesions stained positively for the macrophage marker
F4/80, while the SCC lesions stained positively for MPO, a marker
of tumour-associated neutrophils (Supplementary Fig. 1c).
Our first set of experiments demonstrated that Lkb1 deletion
in cells that had KRAS activation long before was sufficient
to produce tumours with squamous characteristics. It was
tempting to speculate that this was evidence of a true transition
from a KRASþ ADC cellular state to a KRASþ /Lkb1-null
squamous state. However, because the two genetic manipulations
were performed on cells that remained within the same mouse
during the entirety of the process, the possibility remained
that Lkb1 deletion was allowing growth of a latent population
of squamous-predisposed KRASþ cells. To address this issue,
we isolated KRASþ lung ADC cells prior to tamoxifen treatment
and transplanted them into immunocompromised mouse
recipients (Fig. 2a). Cohorts of mice received either tamoxifen
or placebo were aged until signs of tumour distress, and were then
assessed for tumour histology. The tamoxifen naı¨ve cohort
uniformly presented with ADC, which could be serially
transplanted and never transitioned to SCC (Fig. 2b). In contrast,
upon tamoxifen administration 2 weeks after transplant, the
tumours in mice treated with tamoxifen took on squamous
characteristics, with 40% of mice having at least one lesion
that was completely SCC at the time of killing (P¼ 0.0225 Tam
versus no Tam, Fig. 2c). In our previous studies, we observed
that KRAS tumour propagating cells (TPCs) were present in
both Sca1þ and Sca1- compartments, and a purely squamous
model generated by bialleleic inactivation of Lkb1 and
Pten (Lkb1/Pten) harboured Sca1þ and NGFRþ TPCs37. To
explore these populations in the transplanted tumours, we
collected tumours from each mouse, dissociated and analysed
EpCAMþ /CD31 /CD45 cells for expression of NGFR and
Sca1. We observed that KRAS transplant tumours had very
few Sca1þ /NGFRþ cells and were indistinguishable from
adeno-Cre induced KRAS tumours (P¼ 0.368; Fig. 2d and
Supplementary Fig. 2a,b). By contrast, tamoxifen-treated mice
harboured tumours with high levels of Sca1 and NGFR, and
the population of Sca1þ /NGFRþ cells was the same proportion
of tumour as found in the pure Lkb1/Pten SCC tumours
(P¼ 0.004 Tam versus no Tam, P¼ 0.720 Tam versus
Lkb1/Pten). We also confirmed cell surface NGFR staining in
the tamoxifen-treated mouse tumours by IHC (Supplementary
Fig. 2c). Lastly, we isolated cells from squamous transitioned
lesions for transplant, and found that both Sca1HighNGFRHigh
and Sca1HighNGFRLow tumour cells could successfully transplant
squamous disease (Fig. 2e). Together these data demonstrate
that purely ADC lesions derived from transplanted KRASþ cells
can transition to SCC, and that tumours can acquire the
SCC TPC expression profile of Sca1þ /NGFRþ upon Lkb1
deletion. Once the squamous transition has happened, the
phenotype perpetuates.
Loss of PRC2 activity accompanies SCC transition. We
hypothesized that the switch from ADC to SCC could be
controlled in part through epigenetic mechanisms. The decreased,
yet not absent, expression of TTF1 in the SCC lesions could be
indicative of epigenetic memory of prior TTF1 positivity before
the squamous differentiation process occurred, as was observed in
other studies30. To examine the possibility that an epigenetic
mechanism such as PRC gene repression was involved in
the ADC-SCC transition, we performed western blots for
the common methylation marks catalysed by PRC, H3K27me1,
H3K27me2 and H3K27me3, on whole tumour extracts
from KRAS-induced ADCs (no tamoxifen), KRAS/Lkb1 ADCs
and KRAS/Lkb1 SCCs (both tamoxifen at 10 weeks post FlpO).
When compared to KRAS ADC or KRAS/Lkb1 ADC, there
was a marked increase in histone H3 lysine 27 mono-methylation
(H3K27me1) accompanied by a decrease in H3K27me3 in the
KRAS/Lkb1 SCC lesions (Fig. 3a). We next examined expression
of the components of the PRC2, the protein complex that
catalyses the H3K27me3 mark, by western blotting. Interestingly,
although SCC lesions have higher levels of the methyltransferase
EZH2 than the ADC lesions, there is a clear lack of the essential
PRC2 subunit EED in the SCC lesions (Fig. 3b). In a published
data set from KRAS ADC, KRAS/Lkb1 ADC and KRAS/Lkb1
SCC31, transcriptional levels of EED were not significantly
different, suggesting regulation of protein stability. To explore
this inverse correlation between EZH2 and H3K27me3
expression, we performed immunostaining for the two markers
on serial tumour sections from KRAS/Lkb1 adenosquamous
tumours, Pten/Lkb1/p53 adenosquamous tumours and Pten/Lkb1
squamous tumours (Fig. 3c). Consistently, we observed that ADC
regions had sparse EZH2 staining and robust H3K27me3
staining. In contrast, squamous lesions on the same slides
showed higher levels of EZH2 staining, and lower, but not absent,
H3K27me3 staining (Fig. 3d and Supplementary Fig. 3a). We
performed similar staining on human tumours, including six
confirmed cases of adenosquamous cancer (Fig. 3e). Again, the
pattern of higher EZH2 and slightly lower, but not completely
absent, H3K27me3 was present in squamous lesions as compared
to ADC lesions, which were H3K27me3 high and had lower
levels of EZH2 (Fig. 3f and Supplementary Fig. 3b). While
analysing these sections, we noted that normal airway and
alveolar epithelium shared the ADC staining pattern of high
H3K27me3 and low EZH2, while the oesophagus, which is the
closest stratified squamous organ to the lung, had increased EZH2
staining and lower H3K27me3 (Supplementary Fig. 3b). This
observation implies that normal lung epithelium may be
maintained in a glandular state by PRC2 gene repression, and
that loss of H3K27me3 gene repression may de-repress
a programme predisposed to the squamous cell sate.
Despite the obvious lack of EZH2’s catalytic mark, higher levels
of EZH2 in the squamous tumours suggested that EZH2 may be
required for squamous tumour growth and could represent
a therapeutic target. Therefore, we bred the Ezh2 floxed alleles38
to the Cre-based LSL:KrasG12D; Lkb1flox/flox model. We
generated three genotypes with the Kras/Lkb1 alleles in the
setting of Ezh2þ /þ , Ezh2flox/þ or Ezh2flox/flox alleles (Fig. 4a).
Cohorts of these genotypes were analysed for tumour histology 11
weeks post Adeno-Cre virus administration. While the Ezh2þ /þ
and Ezh2flox/þ cohorts both hadB40% of mice with at least one
purely squamous lesion at this time-point, all of the mice
from the Ezh2flox/flox cohorts had squamous lesions (Fig. 4b,c).
We confirmed that both H3K27me3 and EZH2 were decreased
in these Ezh2flox/flox tumours by IHC (Supplementary Fig. 4a,b).
This result suggests that EZH2 is dispensable for the squamous
state, and that loss of the PRC2 complex activity could potentiate
the switch to SCC. This result is unique from those observed
when the PRC2 complex was depleted in KRAS or KRAS/p53
tumours—without Lkb1 deletion the squamous phenotype
does not appear39.
The genetic results described above suggest that loss of EZH2
function can perpetuate the squamous fate over several weeks
of tumour development. We next wanted to test if inhibiting
the catalytic function of EZH2 with a small molecule could
drive the acquisition of squamous markers in short-term in vitro
cultures. We first treated the human ADC cell line A549, which
has the genotype of KRASG12S, LKB1Q37* with the inhibitor
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GSK126 (ref. 40). As measured by flow cytometry, the NGFRþ
cells within this cell line increased from 4.9 to 20.4% after 6 days
in 10mM GSK126 (Po0.0001, Fig. 4d). RNA from the treated
A549 cells likewise showed a fourfold increase in NGFR
transcript level in response to GSK126 relative to vehicle-treated
cultures, consistent with a de-repression of EZH2-mediated
silencing of the locus (P¼ 0.0004; Fig. 4e). Although the
LSL:KrasG12D cells that are WT for p53 are not able to grow
as two-dimensional adherent cultures, they can be grown as
three-dimensional (3D) cultures37. We confirmed that growing
3D tumour organoids derived from FlpO induced KRAS lesions
in 100 nM 4-hydroxy tamoxifen was able to drive deletion of the
Lkb1 allele, making this a tractable system in which to observe the
early changes associated with Lkb1 loss (Supplementary Fig. 4c).
Firstly, we observed an increase in organoid re-seeding ability
with tamoxifen treatment, consistent with the acquisition of more
aggressive tumour characteristics upon Lkb1 deletion in vivo
(P¼ 0.04; Fig. 4f and Supplementary Fig. 4d). Whereas KRAS
tumour organoids were significantly decreased when passaged in
continued 5 mM GSK126, organoids grown in the presence
of tamoxifen (and therefore Lkb1 null) were equally passaged
in continued presence of the EZH2 inhibitor (P¼ 0.0113 for
Kras, P¼ 0.132 for KRAS/Lkb1; Supplementary Fig. 4d). Lastly,
we observed that treating cultures with tamoxifen for 9–12 days
(primary organoids) and re-seeding the cells in drug for
an additional 9–12 days (secondary organoids) led a marked
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decrease in Lkb1 expression and an increase in Sox2, Ngfr and
Sca1 expression (Fig. 4g and Supplementary Fig. 4e).
Interestingly, GSK126 treatment potentiated the increase in
both Sca1 and Sox2, consistent with loss of H3K27me3
transcriptional repression allowing the SCC transition process.
Chromatin landscapes reveal de-repression of squamous genes.
To characterize the chromatin landscapes of KRAS/Lkb1
tumours, we performed chromatin immunoprecipitation (ChIP)
on microdissected tumours confirmed to be either ADC or
SCC by histology and qPCR (Supplementary Fig. 5a). The two
activating marks, histone H3 lysine 4 tri-methylation (H3K4me3)
and histone H3 lysine 27 acetylation (H3K27ac), and the PRC2-
derived silencing mark, histone H3 lysine 27 tri-methylation
(H3K27me3) were immunoprecipitated, followed by sequencing
the chromatin bound DNA (ChIP-seq). ADC and SCC tumours
could be clearly distinguished by differential H3K4me3
enrichment (Fig. 5a). Of the most significantly differential
enrichment on H3K4me3 and/or H3K27ac marks between
SCC and ADC tumours (Supplementary Fig. 5c and Suppleme-
ntary Tables 1–4), we found much higher load of H3K27ac and
H3K4me3 marks in the SCC tumour compared to the
ADC tumour on the squamous genes Sox2, DNp63, Ngfr and
Krt5/6 (Fig. 5b and Supplementary Fig. 5a). Furthermore, we
observed a significantly lower level of H3K27me3 mark in Sox2,
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Ngfr and Krt5/6 loci compared to those in ADC tumours,
consistent with de-repression of these squamous loci in
SCC tumours (Fig. 5b). The differentially enriched regions for
active histone marks also included the loci for the neutrophil
chemoatractants Cxcl3/5, and the interferon-response induced
Ifitm1/2/3, which were higher in the SCC tumours (Supple-
mentary Fig. 5a). For ADC, the known expressed genes Scgb1a1,
Foxa2 and SftpB had activating marks which were lost is
SCC (Supplementary Fig. 5b). We also used the ROSE
algorithm41 to call super-enhancers, many of which were shared
between ADC and SCC, indicating that the tumours share
some epigenetic memory (Supplementary Tables 5 and 6).
For ADC, a unique super-enhancer was called at Scgl1a1, while
Ifitm3 was a unique super-enhancer for SCC (Supplementary
Tables 5 and 6). We next ran GREAT42 on the significantly
enriched H3K4me3 loci in SCC tumours and found that the
genes adjacent to these loci are enriched for H3K27me3,
methylated CpG islands and PRC2 components in human
embryonic stem cells and murine embryonic fibroblasts,
suggesting that the activated loci in SCC tumours are normally
repressed by PRC2 in other cell types (Fig. 5c). A closer
examination of the H3K27ac-enriched regions in each tumour
type indicated that unlike the H3K27ac-marked loci that were
common to all samples, which were devoid of H3K27me3, the
uniquely SCC- or ADC-enriched loci were very often bivalently
marked with H3K27me3 and H3K37ac in ADC, and became
monovalently marked with H3K27ac in SCC due to a loss of
PRC2-mediated gene repression (Sox2 is an example) (Fig. 5d).
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BASCs and club cells are cells-of-origin for SCC transition. We
reasoned that the ‘choice’ of cells to transition to the squamous
fate upon Lkb1 deletion may be predetermined by the tumour
cell-of-origin. To test this theory, we used a fluorescence activated
cell sorting (FACS) approach to enrich for populations of lung
cells that are likely tumour cells-of-origin and which can be
easily enriched using cell surface markers, including tracheal
basal cells (enriched using positive selection for NGFR),
non-basal cells of the trachea (the NGFR- fraction from the
trachea that contains club, ciliated and goblet cells23,43), distal
lung BASCs (enriched in the EpCAMþ Sca1þ fraction) and
distal lung alveolar type II (AT2) cells (enriched in the EpCAMþ
Sca1- fraction)12,21 (Fig. 6a and Supplementary Fig. 6a). To
directly test the fitness of each population to propagate after
activation of oncogenic KRAS we incubated each FACS-isolated
population with no virus, adeno-GFP virus or adeno-FlpO virus
before plating for organoid cultures12,20 (Fig. 6b and
Supplementary Fig. 6b). Strikingly, while the non-basal cells,
BASCs and AT2 populations were all able to give rise to
organoids after KRAS activation (Fig. 6c–d and Supplementary
Fig. 6c), the basal cell population was consistently unable to
produce any organoid after adeno-FlpO virus (Fig. 6c,d, n¼ 4).
Visual inspection of the basal cell cultures showed single
non-dividing cells several days after plating. The non-basal
cells, despite having a dramatically decreased organoid forming
efficiency compared to basal cells, were consistently able to
grow robust KRASþ organoids (Fig. 6c–e). Both non-basal
and BASC-derived organoids were predominantly bronchiolar
in phenotype, while AT2-derived organoids were alveolar
(Supplementary Fig. 7a).
Having formed KRASþ organoids with our in vitro culture
system, we next sought to delete Lkb1 in these cultures and
assess if organoids could take on squamous characteristics.
To accomplish this, we serially passaged the cultures and
added 100 nM 4-hydroxy tamoxifen to the transwell culture
media (Fig. 7a). The non-basal cell-derived and BASC-derived
cultures continued robust growth in tamoxifen, but the
AT2-derived cultures reproducibly failed to grow in tamoxifen
(Fig. 7b and Supplementary Fig. 7a). Tamoxifen administration to
AT2-derived cultures from WT mice continued to grow normally
d
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(data not shown), suggesting that tamoxifen itself was not
detrimental and that KRASþ AT2 cells cannot tolerate loss
of Lkb1. We confirmed Lkb1 mRNA levels were decreased
by tamoxifen administration in non-basal cell and BASC-derived
cultures, and also that Sox2 gene expression was increasing
in these cultures, though Sox2 expression was variable (Fig. 7c).
The variability of Sox2 increase fit with the observation that
only some organoids in each culture took on squamous
characteristics (Supplementary Fig. 7b). Lastly, to demonstrate
that we had taken a normal cell population and transformed it to
a fully malignant state in vitro, we subcutaneously transplanted
cells from the non-basal cell-derived cultures into immunocom-
promised mice. Large tumours formed (4500mm3), and upon
histological examination, these tumours had regions of squamous
differentiation right next to regions of ADC differentiation
(n¼ 2; Fig. 7d). We also transplanted cells orthotopically from
BASC-derived cultures, while one mouse had solely squamous
differentiated tumour, the other had solely mucinous
ADC (n¼ 2, Fig. 7d and Supplementary Fig. 7c). Therefore,
our experiments rule out the basal cells and AT2 cells as likely
cells-of-origin for adenosquamous tumours, whereas both
non-basal tracheal cells and distal lung BASCs could drive
squamous disease.
Discussion
Lung cancer lineage plasticity is an emerging concept that
could influence the diagnosis and treatment of this devastating
disease. In this manuscript, we used a unique model system
to study lineage switching in KRAS-driven tumours in response
to Lkb1 deletion. To validate the clinical utility of our model,
we first examined a cohort of ADSCC lung cancer, finding that
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the LKB1 mutation was present in more than one quarter of
the patients. We next demonstrated that KRAS-driven ADCs,
either in the autochthonous setting or after transplant, retained
the ability to transition into squamous tumours when Lkb1 was
deleted many weeks or months after KRAS induction. We further
demonstrated that a loss of PRC2-mediated gene repression was
a hallmark of the lineage switched SCC tumours. Lastly, our lung
organoid data suggest that a combination genetic alterations,
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epigenetic state and cell-of-origin ultimately determine tumour
phenotype (Fig. 7e).
Our data indicate that after Lkb1 is deleted in established
KRAS ADCs, epigenetic reprogramming drives cells to take on
squamous characteristics, ultimately resulting in full squamous
transition of some tumours. These transitioned SCC tumours
are characterized in both the mouse and human by a loss of
the PRC2 H3K27me3 repressive chromatin mark, leading to
activation of previously bivalently marked chromatin regions.
Loss of PRC2-mediated gene repression leads to activation
of squamous transcriptional programme, including the key
squamous-associated genes Ngfr, Sox2, DNp63 and Krt5/6.
Sox2 and DNp63 are both well known to drive the squamous
fate44–47. Thus, it is likely derepression of these genes that
allows perpetuation of the squamous fate after the initial
transition has occurred.
EZH2, which is the PRC2 methyltransferase that catalyses
H3K27me3, has been proposed to be an oncogene in both lung
ADC and SCC because its expression is correlated with poor
prognosis of both histologies and its overexpression can drive
ADC in mouse models39,48–50. Intriguingly, we and others have
observed a decoupling of EZH2 expression levels from
H3K27me3 levels in cancers51–53. In ADC regions, high and
uniform H3K27me3 was found with relatively low expression of
EZH2. It may be possible that EZH2 is only expressed in
proliferating cells to replace the H3K27me3 marks lost during
division. In SCC regions, there was often high EZH2, but lower
levels of H3K27me3 mark than in ADC regions. We determined
that reduction of H3K27me3 in SCCs was likely due to
downregulation of the PRC2 component EED. EED loss may
be the key to maintain an EZH2 high/H3K27me3 low state in
other tumour types, or even in normal cells such as the
oesophageal epithelium, and will warrant more study in the
future. Because EZH2 was overexpressed in SCC tumours, it
remained possible that EZH2 was critical for maintenance of the
squamous fate with roles outside of the PRC2 complex, as has
been observed in other tumour types54–56. However, genetic
depletion of Ezh2 actually potentiated KRAS/Lkb1 SCC tumour
growth, and EZH2 inhibition had no effect on KRAS/Lkb1
3D cultures. These data are supported by a recent study that
demonstrated that Eed deletion accelerates KRAS/p53 tumour
development by driving a switch to mucinous ADC39. Both of
these studies suggest that the PRC2 complex may act as a tumour
suppressor in lung cancer by limiting lineage identity.
There has been much controversy over the possible cells-of-
origin of subtype and genotype-specific lung tumours. After
using intranasal adenovirus-Cre to induce oncogenic KRAS, the
first hyperproliferative cells observed were BASCs, implicating
this population as possible ADC cells-of-origin19. More recent
studies with lineage-specific KRAS activation in vivo suggested
that AT2 cells appeared to be the only cells capable of giving rise
to advanced ADC in the alveolar space, while club cells and
BASCs appeared to be limited to driving bronchiolar hyperplasia
within the same time frame57. Importantly, results varied when
the genotype was altered to include SOX2 activation or
p53 loss58,59. Our data add to this picture by indicating that
NGFRþ basal cells cannot tolerate oncogenic KRAS. Given
that basal cells express high levels of EGFR37, and that
KRAS activation and EGFR activation cannot be tolerated by
the same cell60, it is conceivable that basal cells undergo
oncogene-induced senescence upon KRAS activation. In the
more distal lung, we observed that both AT2 cells and BASCs
could efficiently form KRASþ organoids. However, the
AT2-derived cultures could not proliferate after Lkb1 deletion.
It was the non-basal cells of the trachea, a population enriched
for club, ciliated and goblet cells23,43, and the BASCs of the
distal lung that could survive both KRAS activation and
Lkb1 deletion. Both cell types gave rise to organoids that
could grow in vivo, with some ADC and some SCC histology.
These findings are in strong agreement with a recent paper
using cell type restricted Cre virus, which also found the club
cells to be more likely cells-of-origin of adenosquamous tumours
of the KRAS/Lkb1 genotype36. These results are consistent
with recent evidence that both CCSP and SPC expressing
cells can give rise to SCCs with activation of SOX2 and
inactivation of Pten and Cdkn2a45. Overall our data suggest
that club cells and BASCs are the most likely cells of origin
of KRAS/Lkb1 ADSCC, and that further characterization of
these cell types in their normal state and in the context of
oncogenic activation will shed new light on the subtype of
adenosquamous cancer in patients.
What remains unclear is what why certain cells respond
to Lkb1 deletion by downregulation EED and ultimate loss of
PRC2-mediated gene repression of the squamous transcriptional
programme. Because LKB1 affects many metabolic processes,
one possibility is that metabolism of methionine is a link between
LKB1 and EED. Studies with an inhibitor of S-adenosyl
homocysteine hydrolase have demonstrated that decreased
methionine metabolism can cause destabilization of the PRC2
components at the protein level61. Future studies will focus on
identifying the link between the cellular genotype and the
epigenetic identity of lung cancer cells from different subtypes
of lung cancer, including ADC, SCC and ADSCC, with the
ultimate goal of identifying unique vulnerabilities of each that
can be used in new therapeutic approaches.
Methods
Mouse cohorts. Mouse cohorts of Lkb1flox/flox/Ptenflox/flox; LSL:KrasG12D/þ ,
LSL:Kras G12D/þ ; Lkb1flox/flox, and FSF:KrasG12D/þ ; FSF:R26:CreERT2;
Lkb1flox/flox and LSL:Kras G12D/þ ; Lkb1flox/flox, Ezh2floxed were all maintained in
virus-free conditions on a mixed 129/FVB background. FSF:KrasG12D (Krastm5Tyj)
mice were purchased from The Jackson Laboratory; Foxn1/Foxn1Nu/Nu mice
were purchased from Charles River Laboratories International Inc. All care and
treatment of experimental animals were in strict accordance with Good Animal
Practice as defined by the US Office of Laboratory Animal Welfare and approved
by the Dana-Farber Cancer Institute Institutional Animal Care and Use
Committee. Mice were given 2 108 pfu of Adeno-FlpO virus via intranasal
infections at 6–8 weeks old. Mice were administrated daily by intraperitoneal
injection of tamoxifen-free base (SIGMA T5648) in corn oil (12 mgml 1) at 132 mg
tamoxifen per gram of body weight per day for five consecutive days. Magnetic
resonance imaging scan was used for mouse lung tumour burden measurement as
previously described37. Intratracheal transplants were performed as described62.
Mice were monitored for signs of lung tumour onset and killed for gross and
histological analysis and tumour isolation upon signs of distress.
Flow cytometry analysis and sorting. Tumours were dissected from the lungs of
primary mice and tumour tissue was prepared as described62. Single-cell
suspensions were stained using rat-anti-mouse antibodies. Antibodies for tumour
cell analysis included anti-human-NGFR (EMD Millipore 05-446) coupled with
goat-anti-mouse-PECy7 (BioLegend 405315), anti-mouse-NGFR (AbCAM
ab8875) coupled with donkey-anti-rabbit-PE (eBiosciences 12-4739-81), anti-
mouse-Sca1-APCCy7 (Fisher Scientific BDB560654), anti-mouse-EpCAMPECy7
(BioLegend 118216), anti-mouse-CD31-APC (Fisher Scientific BDB551262) and
anti-mouse-CD45-APC (Fisher Scientific BDB559864). Live cells were gated by
exclusion of 40,6-diamidino-2-phenylindole (DAPI)-positive cells (SIGMA).
Immune cell analysis is described in a previous study63. All antibodies were
incubated for 10-15 min at 1:100 dilutions for primaries and 1:200 for secondary
antibodies. Cell sorting was performed with a BD FACS Aria II with an 85mm
nozzle, and flow cytometric analysis was performed with a BD Fortessa and data
were analysed with FlowJo software (Tree Star).
In vitro FlpO and stem cell organoid culture. Cells isolated by flow cytometry
as described above were split into equal aliquots, pelleted by pulse spin and
resuspended in 100ml MTEC plus media with 6 107 PFU per ml 1 of
Adeno-FlpO or Adeno-GFP or no virus. Cell numbers for each condition/well
ranged from 1,000–10,000 basal cells, 2,000–10,000 non-basal cells, 33,000–100,000
AT2 cells and 2,000–20,000 BASCs. These suspensions were incubated at 37C,
5% CO2 for 2 h in 1.5ml tubes. Mock-infected cells (no virus) were also incubated
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for the same time to control for anoikis. Cells were then pelleted by pulse spin and
resuspended in 1 phosphate-buffered saline (PBS) twice to wash and finally
resuspended for 3D culture. Tracheal cells were cultured as described in ref. 12,
with additional 25 ngml 1 rmFGF2 (RþD Systems 3139-FB/CF) and in a total
starting volume of 100 ml of cells in media mixed with 100 ml of growth factor
reduced Matrigel (Fisher Scientific). Previously it was demonstrated that distal
lung stem cells can differentiate into lineage-specific organoids when grown in
cultures with primary lung endothelial cells (see ref. 20), and we employed these
cultures for NGFRþ and NGFR- BASCs as well as AT2 cells. Tracheal cells
grown in the same endothelial cell cultures grew similarly hollow spheres
composed of basal-like p63þ cells, what appear to be lineage-negative cells
and ciliated cells, just as they do in the MTEC media.
Immunofluorescence on organoid cultures. Cultured colonies were fixed with
10% neutral-buffered formalin in overnight at room temperature. After rinsing
with 70% ethanol, fixed colonies were immobilized with Histogel (Thermo
Scientific) for paraffin embedding. Sectioned embedded colonies were stained
with haematoxylin and eosin and immunostained with antibodies for CCSP
(1:200, Santa Cruz clone T-18), pro-SPC (1:200, Santa Cruz clone FL-197), p63
(1:200, Biocare clone 4A4), acetylated-tubulin (1:1,000; Sigma, clone 6-11B-1).
Secondary antibody staining included donkey a-mouse 488, donkey a-rabbit 594,
donkey a-goat 647 (1:400, Invitrogen) and Prolong Gold with DAPI (Life
Technologies).
Tumour cell 3D culture. Dissociated tumour cells were resuspended in DME/F12
media (GIBCO) containing 1 penicillin/streptomycin (Invitrogen), 4mM
L-glutamine (Invitrogen), 10% fetal bovine serum (HyClone), 10 mgml 1 insulin
(SIGMA I-6634), 1 insulin/transferrin/selenium mixture (Corning 25-800-CR),
12.5 mgml 1 bovine pituitary extract (Invitrogen 13028-014), 0.1 mgml 1 cholera
toxin (SIGMA C-8052), 25 ngml 1 mEGF (Invitrogen 53003018) and 25 ngml 1
rmFGF2 (RþD Systems 3139-FB/CF), mixed 1:1 with growth factor-reduced
Matrigel (Fisher Scientific), and pipetted into a 12-well 0.4 mm Transwell insert
(Falcon). MTEC/Plus (described above) medium (500 ml) was added to the lower
chamber and refreshed every other day. GSK126 was purchased from Xcess Bio as
a 10mM solution in DMSO, and 4-hydroxy-Tamoxifen (SIGMA) was resuspended
to a concentration of 100mM in sterile 100% ethanol. Both were diluted
1:1,000–1:2,000 into tissue culture media for use.
Quantitative RT PCR. RNA from treated cell lines was extracted using Absolutely
RNA kits (Agilent) and cDNA was made using the SuperScript III kit (Invitrogen).
Relative gene expression was assayed with Taqman probes on the StepOnePlus
Real-Time PCR System (Applied Biosystems). Relative expression was calculated
by Gene of Interest (CtreferenceCtexprimental)CYPA(CtreferenceCtexperimental)
and graphed on the log2 scale or converted to linear scale. Statistics were performed
on log2 data. For all experiments, the reference sample was a matched vehicle
treated or control transduced cell line.
Statistical analysis. Statistical analyses were carried out using GraphPad Prism.
All numerical data are presented as mean±s.e.m. Grouped analysis was performed
using two-way ANOVA. Column analysis was using one-way ANOVA or t-test.
A P-value less than 0.05 was considered statistically significant.
Histology and immunohistochemistry. Mice were killed with CO2 and the right
lobe was dissected and snap-frozen for biochemical analysis. The remainder of
the lungs was inflated with neutral-buffered 10% formalin overnight at room
temperature, and then transferred to 70% ethanol, embedded in paraffin and
sectioned at 5 mm. Haematoxylin and eosin stains were performed in the
Department of Pathology in Brigham and Women’s Hospital. Tumour burden
analysis was performed with ImageJ software. Immunohistochemistry was
performed as previously described37. Antibodies used for other markers are
listed below: LKB1 (Cell Signaling 3047S), TTF1 (DAKO M3575), p63
(AbCAM ab53039), SOX2 (Millipore AB5603), NGFR (Epitomics 1812-1), MPO
(Novus R-1073), F4/80 (eBioscience 14-4801-82) and p63 (Santa Cruz sc-25268).
Scoring of H3K27me3 (Cell Signaling 9733) and EZH2 (Cell signaling 5246S)
nuclear staining was performed with Nikon NIS-Elements AR software.
Magnification images of  20 or  40 were captured of both ADC and
SCC regions as judged by a pathologist. Regions of stroma (blood cells, vessels,
fibroblasts and connective tissue) were deleted from the images by hand, prior to
using the dot detection module to quantify all nuclei on the red channel, and to
quantify stained nuclei with increasing stringency on the blue channel. Visual
confirmation of one dot per nucleus and cutoff for stained signal were confirmed
by the user for each set of images. Importantly, cutoff settings remained the same
for ADC and SCC images from the same slide, allowing direct comparison of
staining intensities in the mixed adenosquamous cases. Percentages of positive
nuclei were quantified and graphed.
Western blot. Whole-cell extracts were made in RIPA buffer (0.5% deoxycholate,
1% IGEPAL-CA630, 0.1% sodium dodecyl sulfate, 150mM NaCl, 50mM Tris-8.1),
lysates were cleared by centrifugation and protein concentrations were
quantified with the Pierce BCA Protein Assay Kit (Thermo). For western blotting,
25 mg of protein extract per sample was denatured with heat and reducing agents,
separated on a 4–12% acrylamide gel (BioRad) and transferred to nitrocellulose
(GE Healthcare). Antibodies used for western blotting were EZH2 (BD Trans-
duction Laboratories 612666, 1:1,000), LKB1 (Cell Signaling 3047S, 1:1,000),
SUZ12 (AbCAM ab12073, 1:1,000), EED (Millipore 09-774, 1:500), JMJD3
(Aviva Systems Biology ARP40101_P050, 1:500), UTX (GeneTex GTX121246,
1:1,000), total Erk1,2 (Cell Signaling Technology 4695S 1:2,000), pERK1,2
(Cell Signaling Technology 4376S, 1:1,000), pAMPK (Thr172) (40H9 Cell
Signaling 2535 1:1,000), Histone H3 (AbCAM ab1791, 1:20,000), H3K27me1
(Millipore 07-448 1:2,000), H3K27me2 (Millipore 07-452 1:2,000) and H3K27me3
(Millipore 07-449; 1:4,000) all incubated overnight at 4 C. b-Actin-HRP
(SIGMA A3854, 1:20,000) was used as a loading control. All antibodies have
detailed species validation available online from vendors. Secondary antibody
Anti-rabbit IgG, HRP-linked Antibody (Cell Signaling 7074, 1:2,000) or
Anti-mouse IgG, HRP-linked Antibody (Cell Signaling 7076, 1:2,000) was
incubated for 1 h at room temperature. After washing, chemiluminescence was
visualized with Western Lightning Plus-ECL (PerkinElmer) and exposed onto
KODAK BioMax XAR film.
Chromatin immunoprecipitation and sequencing (ChIP-seq). Lung tumours
were pulverized, crosslinked with 1% formaldehyde in PBS for 10min at RT,
washed in 5mgml 1 bovine serum albumin in PBS and then in just cold PBS,
re-suspended in lysis buffer (50mM Tris-HCl, pH 8.1, 10mM EDTA, 1% SDS,
1 complete protease inhibitors (Roche)) and sonicated with the Covaris E210 or
S2 sonicator to obtain chromatin fragment lengths of 200-to-1,500 bp judged by
Bioanalyzer DNA High sensitivity kit (Agilent). Fragmented chromatin was diluted
in IP buffer (20mM Tris-HCl pH 8.1, 150mM NaCl, 2mM EDTA, 1% Triton
X-100) and incubated overnight at 4 C with Protein G magnetic beads
(Dynabeads: Life Technologies) that had been pre-incubated with H3K4me3
(Millipore 07-473), H3K27Ac (Abcam ab4729) or H3K27me3 (Cell Signaling
Technologies C36B11) antibodies. Immunoprecipitates were washed six times
with wash buffer (50mM HEPES pH 7.6, 0.5M LiCl, 1mM EDTA, 0.7% Na
deoxycholate, 1% NP-40) and twice with TE buffer. Immunoprecipitated
(or no IP input) DNA was treated with RNase A and Proteinase K on the beads,
recovered in 1% SDS and 0.1M NaHCO3 over a period of 5 h at 65 C, column
purified with DNA clean and concentrator-25 (Zymo Research). After a sonication
to enrich DNA fragment lengths between 100 and 300 bp, 5–10 ng of DNA were
used for the library construction using NEBNext Ultra DNA Library Prep Kit
(NEB E7370). Sequencing was performed on a NextSeq (Illumina) for
38 nucleotides from paired ends according to the manufacturer’s instructions.
ChIP-seq analysis. Sequenced reads were mapped to reference mouse genome
build 38 (mm10), using bowtie2 aligner64. H3K4me3, H3K27Ac modified
regions were identified using MACS (version 1.4.2) as previously described
(Zhang et al., 2008)65, with a P-value cutoff of 10 5 and with default values for
other parameters. Computer code is available upon request. Quantitative
differences of histone modification between ADC and SCC tumours from Kras/
Lkb1 mice were analysed using the MAnorm algorithm66 with a P-value cutoff of
10 10 and 41 log2 fold change for H3K4me3 and H3K27Ac.
Wiggle files with a 10 bp resolution for H3K4me3, H3K27ac and H3K27me3
modifications were generated by MACS v1.4.2 with tag shift and then rescaled
to a larger of total number of uniquely alignable sequences in two data sets. Histone
modification profiles were then generated with the ‘heatmap’ function or the
SitePro module in Cistrome analysis pipeline (http://cistrome.org/). Wiggle files
were also visualized in the Integrative Genomics Viewer (Robinson et al., 2011)67.
To correlate ChIP-Seq and gene set enrichment, peaks were associated with
genes using GREAT42, allowing for a maximum distance of 10 kb between
peak and associated gene, irrespective of directionality. Data are available at
GEO repository (accession number GSE94365).
Patient lung tumours. Between July 2013 and April 2016, 9616 patients
underwent targeted next-generation sequencing (NGS) at the Dana-Farber
Cancer Institute/Brigham and Women’s Hospital with informed consent under
an IRB-approved research protocol. Among these population, 14 patients with
adenosquamous non-small-cell lung cancer and 84 patients with an LKB1mutation
and ADC were identified using the Oncology Data Retrieval System (OncDRS).
OncDRS is an internal system developed at the Dana-Farber Cancer Institute to
integrate clinical and genomic data. All patients provided written informed
consent, and no germline sequencing was performed. Tumour cell sequencing
was performed on tumour DNA extracted from fresh, frozen or formalin-fixed
paraffin-embedded samples and evaluated for single-nucleotide variants and
genomic rearrangements68. The initial gene panel surveyed all exons of the
275 genes in the panel, along with 91 introns across 30 genes for rearrangement
detection. DNA was isolated from tissue containing at least 20% tumour nuclei and
analysed by massively parallel sequencing using a solution-phase Agilent SureSelect
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hybrid capture kit and an Illumina HiSeq 2500 sequencer. Data were analysed by
an internally developed bioinformatics pipeline composed of reconfigured publicly
available tools and internally developed algorithms including Indelocator
http://www.broadinstitute.org/cancer/cga/indelocator and Oncotator69,70.
Samples with a mean target coverage of o50 were excluded from further
analysis. Individual variants present at o10% allele fraction or in regions with
o50 coverage were flagged for manual review and interpreted by the
reviewing laboratory scientists and molecular pathologists based on overall
tumour percentage, read depth, complexity of alteration and evidence for
associated copy number alterations.
Data availability. Supporting data are available upon request from the
corresponding authors.
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